Surgical revascularization after fibrinolysis in acute myocardial infarction

The role of invasive therapies in elderly patients with acute myocardial infarction

INTRODUCTION

In elderly patients with acute myocardial infarction, very little is known about the role of surgical myocardial revascularization and percutaneous coronary intervention (invasive therapies--IT), especially in the context of long-term outcomes after hospital discharge.

METHODS

We analyzed 1588 patients with MI who had been included prospectively in a databank and followed for up to 7.5 years. In this population, 548 patients were >70 years old (elderly group--EG), and 1040 were <70 years of age (younger group--YG); 1088 underwent IT during hospitalization, and the remaining 500 were treated medically (conservative therapy--CT). Patients were monitored either by visit or by phone at least once a year. A standard questionnaire was administered to all patients. The impact of IT was analyzed with both non-adjusted and adjusted models.

RESULTS

By the end of the follow-up period, the survival rates for the IT and CT groups were, respectively, 71.9% versus 47.2% in the global population (hazard ratio=0.55, P<0.001), 81.5% versus 66.6% in the YG (hazard ratio=0.68, P=0.018) and 48.8% versus 20.3% in the EG (hazard ratio=0.58, P<0.001). In the adjusted models, the hazard ratios were 0.62 (P<0.001) in the global population, 0.74 in the YG (P=0.073) and 0.64 (P=0.001) in the EG.

CONCLUSION

Long-term follow-up of patients with myocardial infarction revealed that IT during the in-hospital phase was at least as effective in elderly patients as in younger patients.

Cardiac surgery in patients on antiplatelet and antithrombotic agents

The widespread application of antithrombotic agents carries significant potential for inducing excessive peri-operative hemorrhage during cardiac surgery. Specific surgical and medical strategies can be employed to attenuate this bleeding. These antithrombotic agents and anti-hemorrhagic measures will be reviewed in depth.

Guidelines for indications for coronary revascularization in The Netherlands

In 1996 the Minister of Public Health, Welfare and Sports in The Netherlands published a 'Planning Decree Special Interventions in the Heart'. She requested from the professional organizations guidelines for the indications for interventions in the heart. A working group was formed with representatives from the Dutch professional organizations for cardiology and thoracic surgery, to address this issue for patients with coronary artery disease. The working group confirmed the need to discuss all patients who are considered for either elective or emergency revascularization during a multidisciplinary consultation in (or with) one of the specialized Dutch hospitals. During this meeting of the 'heart team', at least one interventional cardiologist and one thoracic surgeon should be present. There are three possible outcomes of the heart team's consultations for each patient: drug therapy only ('conservative management'), coronary surgery or catheter intervention. For each case, the team should indicate the expected benefit, the risk of the intervention, the urgency and the estimated waiting time. The guidelines presented in this paper address these issues for three patient categories: stable angina pectoris, unstable angina pectoris and acute myocardial infarction.

State-of-the-Art Review : Management of Patients Who Require Invasive Procedures Immediately Following Thrombolytic Therapy

In recent years the use of thrombolytic ther apy has been demonstrated to be valuable in the treat ment of patients with acute myocardial infarction. Often, because of the frequency of reocclusion of the infarct- related artery, identification of a treatable vascular le sion, or, rarely, failure of thrombolytic therapy, patients will require more invasive procedures to prevent further ischemic injury to the myocardium. These procedures in clude anything from cardiac catheterization to emergency coronary bypass surgery. The perioperative evaluation and management of patients who have recently received thrombolytic therapy requires an understanding of the changes in coagulation proteins that occur with the use of these therapeutic agents. The appropriate understanding and use of antifibrinolytic agents and blood products will allow for these procedures to be performed safely with a minimum of bleeding complications.

Coronary artery bypass grafting within 30 days of an acute myocardial infarction

Risks and benefits of performing coronary artery bypass grafting (CABG) within 30 days of an acute myocardial infarction (AMI) were examined. In 642 patients operated on between January 1988 and December 1993, emergent CABG was performed in 46 patients for cardiogenic shock mainly for failed thrombolysis in patients with an evolving AMI. The remaining patients underwent urgent (< 72 hours) or elective (> 72 hours) revascularization for failed percutaneous transluminal coronary angioplasty (n = 73), postinfarction angina (n = 381), vein graft stenosis (n = 100), and complications after an AMI (n = 42). In patients who underwent primary CABG for an uncomplicated AMI, the infarct was subendocardial in 68, anterolateral or septal in 200, inferior or posteroinferior in 200, and posterolateral in 32 patients. Early mortality (< 30 days) was 5.9% for the entire series and 0%, 4.5%, 4.5%, 29%, 9%, 8%, 10%, and 26% for the subsets of patients with subendocardial infarct, anterolateral or septal infarct, inferior or posteroinferior infarct, ischemic mitral regurgitation, left ventricular aneurysm, redo CABG, age more than 70 years, and left ventricular ejection fraction less than 0.30, respectively. By multivariate analysis, independent predictors of early mortality were left ventricular ejection fraction less than 0.30, age more than 70 years, and cardiogenic shock.(ABSTRACT TRUNCATED AT 250 WORDS)